Hingorani Sangeeta, Finn Laura S, Pao Emily, Lawler Rick, Schoch Gary, McDonald George B, Najafian Behzad, Sandmaier Brenda, Gooley Ted
Departments of Pediatrics, Gastroenterology, and Pathology, University of Washington, Seattle, Washington; Seattle Children's Hospital, Seattle, Washington; and Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington
Departments of Pediatrics, Gastroenterology, and Pathology, University of Washington, Seattle, Washington; Seattle Children's Hospital, Seattle, Washington; and.
Clin J Am Soc Nephrol. 2015 Jan 7;10(1):12-20. doi: 10.2215/CJN.01840214. Epub 2014 Nov 11.
Graft-versus-host disease (GVHD) is associated with kidney injury after hematopoietic cell transplantation (HCT). Because plasma elafin levels correlate with skin GVHD, this study examined urinary elafin as a potential marker of renal inflammation and injury.
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Urine was collected prospectively on 205 patients undergoing their first HCT from 2003 to 2010. Collections were done at baseline, weekly through day 100, and monthly through year 1 to measure elafin and urine albumin-to-creatinine ratio (ACR). Associations between urinary elafin levels and microalbuminuria, macroalbuminuria, AKI and CKD, and mortality were examined using Cox proportional hazards or linear regression models. Available kidney biopsy specimens were processed for immunohistochemistry.
Mean urinary elafin levels to day 100 were higher in patients with micro- or macroalbuminuria (adjusted mean difference, 529 pg/ml; P=0.03) at day 100 than in those with a normal ACR (adjusted mean difference, 1295 pg/ml; P<0.001). Mean urinary elafin levels were higher in patients with AKI compared with patients without AKI (adjusted mean difference, 558 pg/ml; P<0.01). The average urinary elafin levels within the first 100 days after HCT were higher in patients who developed CKD at 1 year than in patients without CKD (adjusted mean difference, 894 pg/ml; P=0.002). Among allogeneic recipients, a higher proportion of patients with micro- or macroalbuminuria at day 100 also had grade II-IV acute GVHD (80% and 86%, respectively) compared with patients with a normal ACR (58%; global P<0.01). Each increase in elafin of 500 pg/ml resulted in a 10% increase in risk of persistent macroalbuminuria (hazard ratio, 1.10; 95% confidence interval [95% CI], 1.06 to 1.13; P<0.001) and a 7% increase in the risk of overall mortality (95% CI, 1.02 to 1.13, P<0.01). Renal biopsy specimens from a separate cohort of HCT survivors demonstrated elafin staining in distal and collecting duct tubules.
Higher urinary elafin levels are associated with an increased risk of micro- and macroalbuminuria, AKI and CKD, and death after HCT.
移植物抗宿主病(GVHD)与造血细胞移植(HCT)后的肾损伤相关。由于血浆弹性蛋白水平与皮肤GVHD相关,本研究检测尿弹性蛋白作为肾炎症和损伤的潜在标志物。
设计、设置、参与者及测量:前瞻性收集了2003年至2010年接受首次HCT的205例患者的尿液。在基线时、第100天前每周以及第1年每月进行收集,以测量弹性蛋白和尿白蛋白与肌酐比值(ACR)。使用Cox比例风险模型或线性回归模型检查尿弹性蛋白水平与微量白蛋白尿、大量白蛋白尿、急性肾损伤(AKI)和慢性肾脏病(CKD)以及死亡率之间的关联。对可用的肾活检标本进行免疫组织化学处理。
在第100天时,微量或大量白蛋白尿患者至第100天的平均尿弹性蛋白水平高于ACR正常的患者(校正平均差异为529 pg/ml;P = 0.03)(校正平均差异为1295 pg/ml;P < 0.001)。与无AKI的患者相比,AKI患者的平均尿弹性蛋白水平更高(校正平均差异为558 pg/ml;P < 0.01)。HCT后前100天内,1年后发生CKD的患者的平均尿弹性蛋白水平高于无CKD的患者(校正平均差异为894 pg/ml;P = 0.002)。在异基因受者中,第100天时微量或大量白蛋白尿的患者中发生II-IV级急性GVHD的比例也高于ACR正常的患者(分别为80%和86%)(整体P < 0.01)。弹性蛋白每增加50 μg/ml,持续性大量白蛋白尿的风险增加10%(风险比,1.10;95%置信区间[95%CI],1.06至1.13;P < 0.001),总体死亡风险增加7%(95%CI,1.02至1.13,P < 0.01)。来自另一组HCT幸存者的肾活检标本显示远端和集合管肾小管中有弹性蛋白染色。
较高的尿弹性蛋白水平与HCT后微量和大量白蛋白尿、AKI和CKD以及死亡风险增加相关。